Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2020 | 12-2019 | 12-2018 | 12-2017 | 12-2016 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 2,193,700 | 1,617,800 | 1,467,700 | 812,700 | 535,203 |
| Marketable Securities | 1,393,300 | 1,596,500 | 1,342,200 | 596,800 | 503,481 |
| Receivables | 4,114,700 | 2,785,600 | 2,243,200 | 1,974,300 | 1,611,620 |
| Inventories | 1,916,600 | 1,415,500 | 1,151,200 | 726,100 | 399,356 |
| TOTAL | $9,779,100 | $7,689,100 | $6,447,600 | $4,335,000 | $3,180,188 |
| Non-Current Assets | |||||
| PPE Net | 3,221,600 | 2,890,400 | 2,575,800 | 2,358,600 | 2,083,421 |
| Investments And Advances | 3,135,600 | 3,256,800 | 1,755,000 | 1,486,500 | 864,260 |
| Other Non-Current Assets | 1,027,000 | 968,901 | 956,100 | 584,200 | 845,597 |
| TOTAL | $7,384,200 | $7,116,101 | $5,286,900 | $4,429,300 | $3,793,278 |
| Total Assets | $17,163,300 | $14,805,200 | $11,734,500 | $8,764,300 | $6,973,466 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 475,500 | 418,100 | 218,200 | 178,200 | 879,096 |
| Other current liabilities | 1,644,200 | 1,296,400 | 772,100 | 637,200 | 1,178 |
| TOTAL | $2,697,400 | $2,096,600 | $1,442,800 | $1,135,500 | $1,241,495 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,978,500 | 0 | N/A | N/A | N/A |
| Deferred Revenues | 577,700 | 382,100 | 452,500 | 320,100 | 231,664 |
| Other Non-Current Liabilities | 687,100 | 799,700 | 361,700 | 152,000 | 100,385 |
| TOTAL | $3,440,600 | $1,618,900 | $1,534,400 | $1,484,700 | $1,282,726 |
| Total Liabilities | $6,138,000 | $3,715,500 | $2,977,200 | $2,620,200 | $2,524,221 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 107,132 | 110,020 | 109,277 | 107,697 | 106,081 |
| Common Shares | 100 | 100 | 100 | 100 | 110 |
| Retained earnings | 10,893,000 | 7,379,800 | 5,254,300 | 2,946,700 | 1,748,222 |
| Other shareholders' equity | 29,000 | 21,200 | -12,700 | 400 | -13,080 |
| TOTAL | $11,025,300 | $11,089,700 | $8,757,300 | $6,144,100 | $4,449,245 |
| Total Liabilities And Equity | $17,163,300 | $14,805,200 | $11,734,500 | $8,764,300 | $6,973,466 |